Small Molecule Microarrays: Methods and Protocols
Author: Mahesh Uttamchandani
Publisher: Methods in Molecular Biology
Published: 2018-12-05
Total Pages: 274
ISBN-13: 9781493982424
DOWNLOAD EBOOKPosts
Regulation of Cancer Immune Checkpoints
Author:
Publisher:
Published: 2020
Total Pages: 657
ISBN-13: 9789811532672
DOWNLOAD EBOOKThis book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Small-Molecule Transcription Factor Inhibitors in Oncology
Author: Khondaker Miraz Rahman
Publisher: Royal Society of Chemistry
Published: 2018-09-06
Total Pages: 214
ISBN-13: 1782621458
DOWNLOAD EBOOKThis book highlights recent progress in the development of small-molecule inhibitors of oncogenic transcription factors and is relevant for postgraduates, researchers and practitioners.
Acute Leukemias IX
Author: Wolfgang Hiddemann
Publisher: Springer Science & Business Media
Published: 2012-12-06
Total Pages: 606
ISBN-13: 3642593585
DOWNLOAD EBOOKAcute Leukemias IX provides an extended and thorough overview of recent developments in cell biology and experimental therapy for acute leukemias. Following the tradition of the Acute Leukemias series since 1987, this book bridges the gap between basic research and clinical studies and emphasizes that both aspects are equally necessary to achieve improvements, not only in understanding the disease but also in providing better therapy. As a forum for world-wide activities in the field of acute leukemias the volume contains invaluable contributions that provide the reader with new, previously unpublished information.
Kinomics
Author: Heinz-Bernhard Kraatz
Publisher: John Wiley & Sons
Published: 2015-11-16
Total Pages: 364
ISBN-13: 3527337652
DOWNLOAD EBOOKDas umfassende Referenzwerk zur Kinase-Forschung: Ausführlich werden die Themen Kinase-Engineering, Peptidsubstrat-Engineering, das Design von Co-Substraten und Kinasehemmer erläutert sowie deren Anwendung in der Bio- und Pharmaforschung beschrieben.
Heat Shock Proteins in Cancer
Author: Stuart K. Calderwood
Publisher: Springer Science & Business Media
Published: 2007-09-09
Total Pages: 399
ISBN-13: 1402064012
DOWNLOAD EBOOKHeat shock proteins are emerging as important molecules in the development of cancer and as key targets in cancer therapy. These proteins enhance the growth of cancer cells and protect tumors from treatments such as drugs or surgery. However, new drugs have recently been developed particularly those targeting heat shock protein 90. As heat shock protein 90 functions to stabilize many of the oncogenes and growth promoting proteins in cancer cells, such drugs have broad specificity in many types of cancer cell and offer the possibility of evading the development of resistance through point mutation or use of compensatory pathways. Heat shock proteins have a further property that makes them tempting targets in cancer immunotherapy. These proteins have the ability to induce an inflammatory response when released in tumors and to carry tumor antigens to antigen presenting cells. They have thus become important components of anticancer vaccines. Overall, heat shock proteins are important new targets in molecular cancer therapy and can be approached in a number of contrasting approaches to therapy.
HSF1 and Molecular Chaperones in Biology and Cancer
Author: Marc Laurence Mendillo
Publisher: Springer Nature
Published: 2020-04-15
Total Pages: 185
ISBN-13: 3030402045
DOWNLOAD EBOOKProtein homeostasis, or “Proteostasis”, lies at the heart of human health and disease. From the folding of single polypeptide chains into functional proteins, to the regulation of intracellular signaling pathways, to the secreted signals that coordinate cells in tissues and throughout the body, the proteostasis network operates to support cell health and physiological fitness. However, cancer cells also hijack the proteostasis network and many of these same processes to sustain the growth and spread of tumors. The chapters in this book are written by world experts in the many facets of the proteostasis network. They describe cutting-edge insights into the structure and function of the major chaperone and degradation systems in healthy cells and how these systems are co-opted in cancer cells and the cells of the tumor microenvironment. The chapters also cover therapeutic interventions such as the FDA-approved proteasome inhibitors Velcade and Krypolis as well as other therapies currently under clinical investigation to disarm the ability of the proteostasis network to support malignancy. This compendium is the first of its kind and aims to serve as a reference manual for active investigators and a primer for newcomers to the field. This book is dedicated to the memory of Susan Lindquist, a pioneer of the proteostasis field and a champion of the power of basic scientific inquiry to unlock the mechanisms of human disease. The chapter “Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective” is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
Nucleic Acids
Author: Marcelo Larramendy
Publisher: BoD – Books on Demand
Published: 2016-03-16
Total Pages: 222
ISBN-13: 9535122649
DOWNLOAD EBOOKThis edited book, "Nucleic Acids - From Basic Aspects to Laboratory Tools", contains a series of chapters that highlight the development and status of the various aspects of the nucleic acids related to DNA chemistry and biology and the molecular application of these small DNA molecules and related synthetic analogues within biological systems. Furthermore, it is hoped that the information in the present book will be of value to those directly engaged in the handling and use of nucleic acids, and that this book will continue to meet the expectations and needs of all who are interested in the different fascinating aspects of molecular biology.
Translational Research in Cancer
Author: Sivapatham Sundaresan
Publisher:
Published: 2021
Total Pages:
ISBN-13: 9781838805357
DOWNLOAD EBOOKNew Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030
Author: Roots Analysis
Publisher: Roots Analysis
Published: 2018-05-01
Total Pages: 306
ISBN-13:
DOWNLOAD EBOOKThe ‘New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030’ report provides a comprehensive study on the current market and therapeutic potential of the various pharmacological interventions designed against difficult-to-modulate cancer targets. It features an elaborate discussion on the future potential of this evolving domain, focusing on phosphatases, transcription factors, small GTPases (specifically Ras family) and undruggable G-protein coupled receptors (GPCRs). One of the key objectives of the study was to review and quantify the future opportunity for the ongoing product development programs of both small and big pharmaceutical firms. Amongst other elements, the report features: 1) A detailed assessment of the current market landscape of drugs being developed against various undruggable cancer targets, featuring information on the developer, phase of development (clinical, preclinical or discovery stage) of product candidate(s), information on type of molecule(s), biological target(s), mechanism of action, route of administration, and key therapeutic indication(s). 2) Elaborate profiles of key companies (selected based on pipeline strength); each profile features an overview of the company, details on it product portfolio, technology overview (wherever applicable), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical trial information and recent developments) and a comprehensive future outlook. 3) A section on emerging technologies and platforms that are aiding the development of therapies capable of targeting biological molecules which were previously considered as undruggable. 4) A detailed publication analysis on more than 70 research articles that have been published between January 2014 and March 2018, highlighting the key focus areas (biological targets and indications) of the ongoing research activity in this field. 5) An analysis of the partnerships that have been established in this domain in the recent past, covering R&D agreements, license agreements, clinical trial collaborations, mergers and acquisitions, and other relevant agreements. 6) An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings. 7) A compilation of key insights derived based on various parameters; these include [A] a bull’s eye analysis highlighting the distribution of pipeline candidates in terms of phase of development, type of target family and type of molecule [B] a three-dimensional and five-dimensional spider web analyses of candidate therapeutics based on different parameters, namely number of publications, grants awarded to promote development, active clinical trials, current phase of development and the number of companies developing drugs against various undruggable targets, and [C] a world map representation, depicting the most active geographies in terms of the presence of companies developing drug candidates against difficult-to-modulate cancer targets.
